Malaria Molecular Surveillance in Mozambique (Phase 2)

Launched by CENTRO DE INVESTIGACAO EM SAUDE DE MANHICA · Jul 26, 2024

Keywords

ClinConnect Summary

The Malaria Molecular Surveillance study in Mozambique is looking to improve how we track and control malaria, especially in pregnant women and children. Mozambique has a high number of malaria cases, and this study aims to gather important information on how malaria spreads and how well current treatments and tests work. By using advanced genetic methods, researchers plan to help the National Malaria Control Program make better decisions about the best ways to prevent and treat malaria in the country from 2023 to 2030.

To participate in this study, children aged 2 to 10 with fever and confirmed malaria, as well as pregnant women attending their first prenatal visit, can be eligible. Participants will need to give consent, and their families will be involved in the process. Those who join can expect to contribute to important research that could lead to better health outcomes for their communities. It’s important to note that the study is currently recruiting participants, and those with severe malaria symptoms or who have recently received malaria treatment will not be eligible.

Gender

ALL

Eligibility criteria

• • A) CHILDREN AT HEALTH FACILITIES
• Inclusion Criteria:
• • Informed, written consent to participate from the guardian
• • Children 2-10 years of age
• • Fever (axillary temperature ≥37.5ºC) or history of fever in the preceding 24 hours
• • At least one positive parasitological test for malaria diagnosis via RDT (HRP2 or LDH)
• Exclusion Criteria:
• • Unwilling to provide informed, written consent
• • Age \<2 years or \>10 years
• • not resident in study area
• • Any symptoms of severe malaria
• • Negative of both (HRP2 and LDH) parasitological test for malaria via RDT
• • History of antimalarial treatment in the last 14 days
• • B) PREGNANT WOMEN AT ANC
• Inclusion Criteria:
• • Pregnant women attending first antenatal care visit
• • Resident in the study area
• • Pregnant Women older than 12 years old
• • Informed, written consent to participate from participant and/or guardian
• Exclusion Criteria:
• • Unwilling to provide informed, written consent
• • Not resident in study area
• • Any symptoms of severe malaria
• • C) DENSE SAMPLING
• Inclusion Criteria:
• • People \> 6 months of age
• • Fever (axillary temperature ≥37.5ºC) or history of fever in the preceding 24 hours
• • Positive parasitological test for malaria diagnosis via RDT
• • Informed, written consent to participate from participant and/or guardian
• Exclusion Criteria:
• • Any symptoms of severe malaria
• • Negative parasitological test for malaria via RDT
• • Unwilling to provide informed, written consent
• • History of antimalarial treatment in the last 14 days